Resources
3 Results (showing 1 - 3)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 5/26/2021 (updated 4/10/2024)
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 11/17/2021 (updated 4/3/2024)
The National Academies of Science, Engineering, and Medicine defines stigma as a range of negative attitudes, beliefs and behaviors that are associated with certain conditions such as addiction. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has been a leading voice in talking about the “chilling effect” stigma has on our ability to address substance use and addiction in our country. In an April 2020 perspective piece published in the New England Journal of Medicine and in her NIDA blog piece, Dr. Volkow explains how stigma can prevent people from seeking care and can even contribute to their continuing addiction. We encourage our visitors to read Dr. Volkow’s writings as well as to familiarize themselves with the efforts to reduce stigma led by the National Institutes of Health (NIH) including the NIH HEAL InitiativeSM, which has made addressing stigma a key element in their efforts to address opioid addiction.